U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C23H30N2O4.C6H8O7
Molecular Weight 590.6188
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PHOLCODINE CITRATE

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.[H][C@@]12OC3=C4C(C[C@@]5([H])N(C)CC[C@@]14[C@@]5([H])C=C[C@@H]2O)=CC=C3OCCN6CCOCC6

InChI

InChIKey=YQRMJBKLKRYXSC-RNFKYSJUSA-N
InChI=1S/C23H30N2O4.C6H8O7/c1-24-7-6-23-16-3-4-18(26)22(23)29-21-19(5-2-15(20(21)23)14-17(16)24)28-13-10-25-8-11-27-12-9-25;7-3(8)1-6(13,5(11)12)2-4(9)10/h2-5,16-18,22,26H,6-14H2,1H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t16-,17+,18-,22-,23-;/m0./s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.phadia.com/Global/ImmunoCAP%20Allergens/Product%20Leaflets/Product_Leaflet_c261_Pholcodine.pdf http://www.ncbi.nlm.nih.gov/pubmed/23773349

Pholcodine is an opioid that has been widely used worldwide since 1950 for the treatment of non-productive cough in children and adults. Illicit drug. Additionally Pholcodine is a marker for sensitization to neuromuscular blocking agents (NMBA) and is intended for use as a diagnostic tool in NMBA-induced anaphylaxis.

Originator

Sources: Chabrier, P., Guidicelli, R. & Thuillier, J. (1950) Etude chimique, pharmacologique et clinique d’un nouveau skdatif de la toux: la morpholyethyimorphine (M.E.M.). Annales Pharmaceutiques Francais. 8, 26 1-273.
Curator's Comment: Reference was retrieved from: http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2710.1988.tb00502.x/epdf

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P33535|||Q64064
Gene ID: 25601.0
Gene Symbol: Oprm1
Target Organism: Rattus norvegicus (Rat)
Target ID: P35372|||G8XRH8|||Q5TDA1|||Q9UN57
Gene ID: 4988.0
Gene Symbol: OPRM1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Pholcodine Linctus B.P.

Approved Use

Cough
Diagnostic
ImmunoCAP® Allergen c261

Approved Use

Anaphylaxis to neuromuscular blocking agents
PubMed

PubMed

TitleDatePubMed
Angle closure risk from proprietary medicines.
2001 Apr
Comparison of eight commercial on-site screening devices for drugs-of-abuse testing.
2001 Jul
Comparative biotransformation of morphine, codeine and pholcodine in rat hepatocytes: identification of a novel metabolite of pholcodine.
2002 Dec
Impurity profiling of pholcodine by liquid chromatography electrospray ionization mass spectrometry (LC-ESI-MS).
2002 Jan
Interpretation of GC-MS opiate results in the presence of pholcodine.
2002 Jun 25
Enzyme immunoassay validation for the detection of buprenorphine in urine.
2003 Mar
The toxicity of opiates and their metabolites in HepG2 cells.
2003 Oct 25
Evaluation of the One-Step ELISA kit for the detection of buprenorphine in urine, blood, and hair specimens.
2004 Jul 16
Prevalence of IgE antibodies to morphine. Relation to the high and low incidences of NMBA anaphylaxis in Norway and Sweden, respectively.
2005 Apr
Allergy to pholcodine: first case documented by oral challenge.
2005 Apr
Automated multiple development thin-layer chromatography for separation of opiate alkaloids and derivatives.
2005 Jul 8
Validated toxicological determination of 30 drugs of abuse as optimized derivatives in oral fluid by long column fast gas chromatography/electron impact mass spectrometry.
2005 Jun
Comparative efficacy and tolerability of pholcodine and dextromethorphan in the management of patients with acute, non-productive cough : a randomized, double-blind, multicenter study.
2006
Pholcodine stimulates a dramatic increase of IgE in IgE-sensitized individuals. A pilot study.
2006 Jan
Site-specific acid-base properties of pholcodine and related compounds.
2006 Nov
Immunoglobulin E antibodies to rocuronium: a new diagnostic tool.
2007 Aug
Pholcodine exposure raises serum IgE in patients with previous anaphylaxis to neuromuscular blocking agents.
2007 Dec
Hypersensitivity reactions to neuromuscular blocking agents.
2008
Determining plasma morphine levels using GC-MS after solid phase extraction to monitor drug levels in the postoperative period.
2008 Jun
IgE-mediated anaphylactic reactions to neuromuscular blocking agents: can they be prevented?
2008 Sep
The pholcodine story.
2009 Aug
Suspected anaphylactic reactions associated with anaesthesia.
2009 Feb
Determination of opiates and cocaine in urine by high pH mobile phase reversed phase UPLC-MS/MS.
2009 Feb 1
On the origin and specificity of antibodies to neuromuscular blocking (muscle relaxant) drugs: an immunochemical perspective.
2009 Mar
Pholcodine caused anaphylaxis in Sweden 30 years ago.
2009 May
Cholinergic and oxidative stress mechanisms in sudden infant death syndrome.
2009 Nov
National pholcodine consumption and prevalence of IgE-sensitization: a multicentre study.
2010 Apr
[Anaphylaxis during anaesthesia].
2010 Mar 11
Clinical expert guidelines for the management of cough in lung cancer: report of a UK task group on cough.
2010 Oct 6

Sample Use Guides

Syrup (1mg/ml pholcodine) Two 5 ml spoonfuls 3 or 4 times a day
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
PHOLCODINE CITRATE
WHO-DD  
Common Name English
Pholcodine citrate [WHO-DD]
Common Name English
CITRIC ACID, COMPD. WITH MORPHOLINOETHYLMORPHINE
Common Name English
MORPHINAN-6-OL, 7,8-DIDEHYDRO-4,5-EPOXY-17-METHYL-3-(2-(4-MORPHOLINYL)ETHOXY)-, (5.ALPHA.,6.ALPHA.)-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE (SALT)
Systematic Name English
Code System Code Type Description
PUBCHEM
70545035
Created by admin on Sat Dec 16 10:48:11 GMT 2023 , Edited by admin on Sat Dec 16 10:48:11 GMT 2023
PRIMARY
CAS
14053-60-2
Created by admin on Sat Dec 16 10:48:11 GMT 2023 , Edited by admin on Sat Dec 16 10:48:11 GMT 2023
NON-SPECIFIC STEREOCHEMISTRY
FDA UNII
K7Z9OPE11S
Created by admin on Sat Dec 16 10:48:11 GMT 2023 , Edited by admin on Sat Dec 16 10:48:11 GMT 2023
PRIMARY